APA (7th ed.) Citation

J, H., T, Z., J, R., & X, W. (2026). The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis. Frontiers in immunology, 17, 1795239. https://doi.org/10.3389/fimmu.2026.1795239

Chicago Style (17th ed.) Citation

J, Hao, Zhang T, Ren J, and Wang X. "The Application of Rituximab During the Conditioning Regimen Prevents Epstein - Barr Virus Infection Following RATG-based Haploidentical Hematopoietic Stem Cell Transplantation in the Era of Letermovir for Cytomegalovirus Prophylaxis." Frontiers in Immunology 17 (2026): 1795239. https://doi.org/10.3389/fimmu.2026.1795239.

MLA (9th ed.) Citation

J, Hao, et al. "The Application of Rituximab During the Conditioning Regimen Prevents Epstein - Barr Virus Infection Following RATG-based Haploidentical Hematopoietic Stem Cell Transplantation in the Era of Letermovir for Cytomegalovirus Prophylaxis." Frontiers in Immunology, vol. 17, 2026, p. 1795239, https://doi.org/10.3389/fimmu.2026.1795239.